Trial Profile
A randomized study of decitabine alternating with clofarabine versus decitabine until failure in patients with higher risk MDS [myelodysplastic syndromes]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Clofarabine (Primary) ; Decitabine (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Genzyme Corporation
- 12 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 May 2015 Planned End Date changed from 1 Feb 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov record.
- 11 May 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov record.